Merck KGaA / Key word(s): Alliance
17.11.2014 08:48
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Merck Announces Global Strategic Alliance with Pfizer on Anti-PD-L1 to
Accelerate Presence in Immuno-Oncology
Merck has entered into a global agreement with Pfizer Inc. (NYSE:PFE) to
co-develop and co-commercialize MSB0010718C, an investigational anti-PD-L1
antibody currently in development by Merck as a potential treatment for
multiple tumor types to accelerate the two companies' presence in
immuno-oncology.
The asset will be developed as a single agent as well as in various
combinations with Pfizer's and Merck's broad portfolio of approved and
investigational pipeline candidates. The two companies will also combine
resources and expertise to advance Pfizer's anti-PD-1 antibody into Phase 1
trials. As part of the agreement, Merck will co-promote Pfizer's XALKORI, a
medicine to treat non-small cell lung cancer, in the United States and
several other key markets. Therefore, the alliance will accelerate Merck's
entry into the US oncology market.
Under the terms of the agreement, Merck will receive an upfront payment of
$ 850 million (approx. EUR 680 million) and is eligible to receive
regulatory and commercial milestone payments of up to $ 2.0 billion. Both
companies will jointly fund all development and commercialization costs and
all revenues obtained from selling any anti-PD-L1 or anti-PD-1 products
generated from this collaboration will be shared.
Certain statements made herein may be deemed to be solicitation materials
in respect of the proposed acquisition of Sigma-Aldrich by Merck KGaA,
Darmstadt, Germany. The proposed acquisition will be submitted to the
stockholders of Sigma-Aldrich for their consideration on December 5, 2014.
In connection therewith, on November 3, 2014, Sigma-Aldrich filed a
definitive proxy statement with the SECand began mailing the definitive
proxy statement to its stockholders of record as of the close of business
on October 29, 2014. BEFORE MAKING ANY VOTING OR ANY INVESTMENT DECISION,
INVESTORS AND STOCKHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT
REGARDING THE PROPOSED TRANSACTION AND ANY OTHER RELEVANT DOCUMENTS FILED
OR TO BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY
BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE
PROPOSED TRANSACTION. Investors and stockholders may obtain free copies of
the proxy statement, any amendments or supplements thereto and other
documents containing important information about Sigma-Aldrich, once such
documents are filed with the SEC, through the website maintained by the SEC
at www.sec.gov. Copies of the documents filed with the SEC by
Sigma-Aldrich will be available free of charge on Sigma-Aldrich's website
at http://investor.sigmaaldrich.com under the heading "Financial
Information-SEC Filings". Stockholders of Sigma-Aldrich may also obtain a
free copy of the definitive proxy statement by contacting Sigma-Aldrich's
Investor Relations Department at (314) 898-4643.
Sigma-Aldrich and certain of its directors, executive officers and other
members of management and employees may be deemed to be participants in the
solicitation of proxies in connection with the proposed transaction.
Information about the directors and executive officers of Sigma-Aldrich is
set forth in its proxy statement for its 2014 annual meeting of
stockholders, which was filed with the SEC on March 21, 2014, its annual
report on Form 10-K for the fiscal year ended December 31, 2013, which was
filed with the SEC on February 6, 2014, and in subsequent documents filed
with the SEC, each of which can be obtained free of charge from the sources
indicated above. Other information regarding the participants in the proxy
solicitation of the stockholders of Sigma-Aldrich and a description of
their direct and indirect interests, by share holdings or otherwise, is
contained in the definitive proxy statement and other relevant materials
filed with the SEC.
17.11.2014 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Merck KGaA
Frankfurter Str. 250
64293 Darmstadt
Germany
Phone: +49 (0)6151 72 - 3321
Fax: +49 (0)6151 72 - 913321
E-mail: investor.relations@merckgroup.com
Internet: www.merck.de
ISIN: DE0006599905
WKN: 659990
Indices: DAX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart;
Terminbörse EUREX; London, SIX
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-Adhoc: Merck KGaA: Merck Announces Global Strategic Alliance with Pfizer on Anti-PD-L1 to Accelerate Presence in Immuno-Oncology
| Source: EQS Group AG